Affiliation: Karolinska Institutet
- [Immunoglobulin or vaccine as post-exposure prophylaxis against hepatitis A. The vaccine is sufficient for many according to the first controlled study]Ola Weiland
Karolinska Institutet, Karolinska Universitetssjukhuset Huddinge, Stockholm
Lakartidningen 105:1371-2. 2008
- Lower-than-standard dose peg-IFN alfa-2a for chronic hepatitis C caused by genotype 2 and 3 is sufficient when given in combination with weight-based ribavirinO Weiland
Division of Infectious Diseases, Department of Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden
J Viral Hepat 15:641-5. 2008..This combination yielded high SVR rates (85-86%) and may be cost-saving...
- Long-term follow-up of chronic hepatitis C patients with sustained virological response to alpha-interferonO Reichard
Department of Infectious Diseases at Danderyd, University Hospital, Karolinska Institutet, Stockholm, Sweden
J Hepatol 30:783-7. 1999..This study aimed to determine the long-term outcome of hepatitis C virus (HCV)-infected patients who respond to interferon treatment with clearance of serum HCV RNA...
- Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological responseT Carlsson
Division of Infectious Diseases, Karolinska University Hospital Solna and Huddinge, Karolinska Institutet, Stockholm, Sweden
J Viral Hepat 12:473-80. 2005....
- Concentration-guided ribavirin dosing with darbepoetin support and peg-IFN alfa-2a for treatment of hepatitis C recurrence after liver transplantationM Ackefors
Division of Infectious Diseases Division of Transplant Surgery Division of Pathology, Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm, Sweden
J Viral Hepat 19:635-9. 2012....
- HCV RNA decline in chronic HCV genotype 2 and 3 during standard of care treatment according to IL28B polymorphismJ Stenkvist
Division of Infectious Diseases, Department of Medicine, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
J Viral Hepat 20:193-9. 2013..This did not translate into a higher frequency of RVR or SVR. Hence, the clinical relevance of pretreatment analysis of IL28B polymorphisms in genotype 2 and 3 infected patients can be questioned in patients with expected high SVR rate...
- Histological findings, genotype distribution and percentage of patients fulfilling the treatment criteria among patients with chronic hepatitis C virus infection in a single Swedish centreA Hollander
Division of Infectious Diseases, Dept of Medicine, Karolinska Institute at Huddinge University Hospital, Stockholm, Sweden
Scand J Gastroenterol 39:164-7. 2004..The aim of this study was to evaluate the genotype distribution, histological stage and grade, and the percentage of patients fulfilling the histological treatment criteria...
- Humoral and CD4(+) T helper (Th) cell responses to the hepatitis C virus non-structural 3 (NS3) protein: NS3 primes Th1-like responses more effectively as a DNA-based immunogen than as a recombinant proteinU Lazdina
Divisions of Clinical Virology, F68, and Biomedical Laboratory Technology, Department of Medicine, Karolinska Institute, Huddinge University Hospital, S-141 86 Huddinge, Sweden
J Gen Virol 82:1299-308. 2001..However, as a DNA immunogen, NS3 elicits stronger Th1-like immune responses, whereas rNS3 primes a mixed Th1/Th2-like response regardless of the route, dose or adjuvant...
- Hepatitis C virus kinetics during induction and standard 3 times a week interferon-alpha therapyT Carlsson
Department of Infectious Diseases, Karolinska Institutet, Stockholm, Sweden
Scand J Infect Dis 33:838-42. 2001..05). We conclude that induction treatment resulted in a significantly greater decline in HCV RNA levels than standard treatment...
- Viral kinetics and treatment response in patients with hepatitis C during induction and standard interferon therapy in combination with ribavirinT Carlsson
Dept of Infectious Diseases, Karolinska Institutet, Karolinska Hospital, Stockholm, Sweden
Scand J Gastroenterol 37:1228-34. 2002..We studied the HCV RNA levels during induction and standard interferon (IFN) and ribavirin treatment...
- DNA vaccine therapy for chronic hepatitis C virus (HCV) infection: immune control of a moving targetMatti Sallberg
Karolinska Institutet at Karolinska University Hospital Huddinge, Division of Clinical Microbiology, F68, Department of Laboratory Medicine, S 141 86 Stockholm, Sweden
Expert Opin Biol Ther 9:805-15. 2009..The vaccination is intended to induce a coordinated immune-based attack on the continuously moving HCV target. If effective, this should help in clearing the infection...
- Expansion of functionally skewed CD56-negative NK cells in chronic hepatitis C virus infection: correlation with outcome of pegylated IFN-alpha and ribavirin treatmentVeronica D Gonzalez
Center for Infectious Medicine, Department of Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden
J Immunol 183:6612-8. 2009..Furthermore, high levels of these cells reveal a disturbance in innate cellular immunity that is associated with an impaired ability to respond to antiviral treatment with IFN-alpha and ribavirin...
- [Long-term treatment with interferon-alpha can induce sarcoidosis. The connection can be stronger than earlier believed]Johan Grunewald
Institutionen für medicin, Solna, Karolinska Institutet
Lakartidningen 103:2045-8. 2006
- Elevated numbers of Fc gamma RIIIA+ (CD16+) effector CD8 T cells with NK cell-like function in chronic hepatitis C virus infectionNiklas K Björkström
Center for Infectious Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
J Immunol 181:4219-28. 2008..Our data suggest that CD8 T cells, during chronic HCV infection in humans, continue to differentiate beyond defined stages of terminal effector cells, acquiring CD16 and NK cell-like functional properties...
- Similar hepatitis C virus RNA kinetics in HIV/hepatitis C virus monoinfected genotype 2 or 3 matched controls during hepatitis C virus combination therapyOlle Karlström
Division of Infectious Diseases, Department of Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden
AIDS 22:899-901. 2008..Sustained virological response was achieved in 9/13 (69%) versus 20/26 (77%) patients (intent-to-treat), respectively. The lower-than-standard peg-IFN dose offered high compliance and reasonable sustained virological response rates...
- Health-related quality of life before, during and after combination therapy with interferon and ribavirin in unselected Swedish patients with chronic hepatitis CAnna Hollander
Division of Infectious Diseases, Department of Medicine, Karolinska Institutet at Karolinska University Hospital Huddinge, Stockholm, Sweden
Scand J Gastroenterol 41:577-85. 2006..To study the relationship between health-related quality of life (HRQOL) and mode of acquisition, treatment discontinuations, drop in haemoglobin levels and treatment outcome in patients with chronic hepatitis C (CHC)...
- Evidence for a relation between the viral load and genotype and hepatitis C virus-specific T cell responsesCatharina Hultgren
Division of Clinical Virology, F68, Karolinska Institutet, Huddinge University Hospital, S 141 86 Huddinge, Sweden
J Hepatol 40:971-8. 2004..The aim of this study is to explore the relation between the viral genotype, viral load, and the endogenous T cell response...
- Codon optimization and mRNA amplification effectively enhances the immunogenicity of the hepatitis C virus nonstructural 3/4A geneL Frelin
Division of Clinical Virology, Karolinska Institutet at Huddinge University Hospital, Stockholm, Sweden
Gene Ther 11:522-33. 2004..Codon optimization and mRNA amplification effectively enhances the overall immunogenicity of NS3/4A. Thus, either, or both, of these approaches should be utilized in an NS3/4A-based HCV genetic vaccine...
- Liver transplantation for HCV cirrhosis at Karolinska University Hospital Huddinge, StockholmH Gjertsen
Department of Transplantation Surgery, Karolinska University Hospital Huddinge, Stockholm, Sweden
Transplant Proc 38:2675-6. 2006..The number of patients with HCV cirrhosis transplanted in our center is increasing. Compared with patients transplanted for other chronic liver diseases, we experienced inferior results among patients with HCV cirrhosis...
- Rapid viral response and treatment outcome in genotype 2 and 3 chronic hepatitis C: comparison between two HCV RNA quantitation methodsTony Carlsson
Division of Infectious Diseases, Department of Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
J Med Virol 80:803-7. 2008..A rapid viral response meaning HCV RNA levels <15 IU/ml predicted a sustained viral response in 97% of patients with genotype 2 or 3...
- High adherence with a low initial ribavirin dose in combination with pegylated-IFN alpha-2a for treatment of recurrent hepatitis C after liver transplantationErika Hörnfeldt
Department of Medicine, Division of Infectious Diseases, Karolinska University Hospital Huddinge, Karolinska Institute, Stockholm, Sweden
Scand J Infect Dis 40:259-65. 2008..Hence, all patients completed a full treatment course, which also offered a reasonable efficacy...
- Productivity improvements in hepatitis C treatment: impact on efficacy, cost, cost-effectiveness and quality of lifeMathias Lidgren
Medical Management Centre, Karolinska Institutet, Stockholm, Sweden
Scand J Gastroenterol 42:867-77. 2007..The treatment of chronic hepatitis C has advanced considerably during the past 15 years. The aim of this study was to evaluate the impact of different key developments from a health-economic perspective...
- Effect of control selection on sustained viral response rates in genotype 2/3 HCV mono-infected versus HIV/HCV co-infected patientsJenny Nilsson
Division of Infectious Diseases, Karolinska Institute, Karolinska University Hospital Huddinge, Stockholm, Sweden
Scand J Infect Dis 42:533-9. 2010....
- GB virus C/hepatitis G virusR Halasz
Division of Clinical Virology, Karolinska Institutet, Huddinge University Hospital, Sweden
Scand J Infect Dis 33:572-80. 2001..Taken together most data suggest that GBV-C/HGV is not a major cause of liver disease despite recent data indicating that it may infect and replicate in hepatocytes...
- Unexpected high prevalence of IgG-antibodies to hepatitis E virus in Swedish pig farmers and controlsBjorn Olsen
Department of Infectious Diseases, Umea University, and Department of Medicine, Karolinska University Hospital Huddinge, Stockholm, Sweden
Scand J Infect Dis 38:55-8. 2006..Further studies are needed to elucidate the routes for infection of indigenous HEV and if sub-clinical infections with pig associated HEV strains occur in Sweden...
- Treatment of chronic hepatitis B infection: an update of Swedish recommendationsMagnus Lindh
Department of Infectious Diseases, Sahlgrenska University Hospital, Goteborg, Sweden
Scand J Infect Dis 40:436-50. 2008..mpa.se and www.rav.nu.se) including 7 separate papers based on thorough literature search. The complete reference list can be received from the Medical Products Agency upon request...
- Serum levels of anti-NS4a and anti-NS5a predict treatment response of patients with chronic hepatitis CIsabelle Desombere
Center for Vaccinology, Ghent University and Hospital, Ghent, Belgium
J Med Virol 79:701-13. 2007..In conclusion, in patients with chronic HCV infection, the decision to continue or stop treatment can be made after 1 week of treatment with (peg)-interferon alpha and ribavirin...
- Prediction of sustained virological response in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) and ribavirinGraham R Foster
The Royal London Hospital, London, UK
Scand J Gastroenterol 42:247-55. 2007..The purpose of this study was to model the probability of achieving a sustained virological response in individual patients, taking into consideration various predictive factors...
- Features of the CD4+ T-cell response in liver and peripheral blood of hepatitis C virus-infected patients with persistently normal and abnormal alanine aminotransferase levelsMiguel A Rico
Institute of Hepatology, Hospital Pardo de Aravaca, Madrid, Spain
J Hepatol 36:408-16. 2002..The liver is the primary site of hepatitis C virus (HCV) replication; intrahepatic T-cell responses may influence liver disease severity...
- Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremiaStefan Zeuzem
Clinic of Internal Medicine II, Department of Medicine, Saarland University Hospital, Kirrbergerstrasse, 66421 Homburg Saar, Germany
J Hepatol 44:97-103. 2006..The aim of the present study was to investigate this schedule in the era of pegylated interferon-alpha plus ribavirin...
- Hepatitis C virus RNA levels during initial induction or standard interferon therapy: influence of continued treatment on sustained responseLigita Balciuniene
Vilnius University, Vilnius University Hospital for Infectious Diseases, Vilnius, Lithuania
Scand J Infect Dis 35:180-5. 2003..Patients with a sustained viral response had a 3-log decline in viral levels at week 4, with few exceptions. Two patients with non-response at week 12 (1 each with genotype 1 and non-1) responded after supplementation with ribavirin...
- Chronic hepatitis C: updated Swedish consensusRune Wejstål
Department of Infectious Diseases, Sahlgrenska University Hospital Ostra, Goteborg, Sweden
Scand J Infect Dis 35:445-51. 2003..Concurrent ART or prominent liver fibrosis requires frequent monitoring because of the increased risk for mitochondrial toxicity and liver failure...
- A low-dose intradermal hepatitis B vaccine programme in health-care workers and students is highly effective and cost saving: a retrospective follow-up survey in the clinical settingPer Sangfelt
Department of Infectious Diseases, Akademiska University Hospital, Uppsala University, Uppsala, Sweden
Scand J Gastroenterol 43:465-72. 2008..To evaluate compliance, serologic response and the cost-benefit of a low-dose intradermal hepatitis B vaccination programme, followed by intramuscular boosters in non-responders...
- Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patientsAlfredo Alberti
J Hepatol 42:615-24. 2005
- Lamivudine and famciclovir combination therapy with or without addition of interferon-alpha-2b for HBeAg-positive chronic hepatitis B: a pilot studyPer Sangfelt
Department of Infectious Diseases, University Hospital, Uppsala, Sweden
Scand J Infect Dis 34:505-11. 2002..In conclusion, lamivudine and famciclovir combination treatment induced seroconversion from HBeAg to anti-HBe in 4/19 patients, 2 of whom became long-term responders. Addition of IFN-alpha did not improve the seroconversion rate...
- Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative studyPierre Pradat
Department of Hepatology, Hotel Dieu, Lyon, France
Hepatology 36:973-7. 2002..In this subset of patients, the indication of liver biopsy and the potential benefit of therapy need to be further evaluated. These results suggest the need to revisit the algorithm for liver biopsy practice...